Ascendis Pharma A/S (ASND) Analysts See $-0.90 EPS

March 14, 2018 - By Hazel Jackson

 Ascendis Pharma A/S (ASND) Analysts See $ 0.90 EPS

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.90 EPS on March, 28.They anticipate $0.35 EPS change or 63.64 % from last quarter’s $-0.55 EPS. After having $-1.22 EPS previously, Ascendis Pharma A/S’s analysts see -26.23 % EPS growth. The stock decreased 0.51% or $0.34 during the last trading session, reaching $66.62. About 81,503 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since March 15, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma had 19 analyst reports since September 26, 2016 according to SRatingsIntel. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Friday, September 22. The rating was maintained by Wedbush on Friday, January 5 with “Buy”. The firm has “Buy” rating given on Monday, February 26 by Wedbush. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Friday, March 24. Wedbush has “Outperform” rating and $34 target. The rating was maintained by Wedbush on Monday, September 11 with “Buy”. The firm earned “Buy” rating on Friday, November 17 by Bank of America. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Outperform” rating by Credit Suisse on Friday, September 22. As per Thursday, February 22, the company rating was maintained by Credit Suisse. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Thursday, September 28 by Wedbush. The firm earned “Outperform” rating on Monday, September 26 by Wedbush.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.77 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: which released: “Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs” on February 22, 2018, also with their article: “Ascendis Pharma A/S Announces Participation in 36th Annual JP Morgan …” published on December 21, 2017, published: “Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference …” on November 02, 2017. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: and their article: “Ascendis Pharma A/S Announces Participation in Evercore ISI 2017 Biopharma …” published on November 21, 2017 as well as‘s news article titled: “Ascendis Pharma A/S (ASND) Reports Dosing of Subjects in Phase 1 Trial of …” with publication date: September 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.